Sana Biotechnology (NASDAQ:SANA) Upgraded at Wall Street Zen

Sana Biotechnology (NASDAQ:SANA) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other equities analysts have also recently weighed in on SANA. Wedbush lifted their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sana Biotechnology in a research note on Monday, December 8th. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. Citizens Jmp increased their price target on Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Thursday, October 30th. Finally, HC Wainwright cut their price objective on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.33.

Sana Biotechnology Price Performance

Shares of SANA stock opened at $4.36 on Friday. The stock has a market cap of $1.16 billion, a PE ratio of -4.49 and a beta of 1.95. The stock has a 50-day moving average of $4.54 and a 200-day moving average of $3.83. Sana Biotechnology has a one year low of $1.26 and a one year high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. As a group, research analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Baillie Gifford & Co. raised its position in Sana Biotechnology by 13.6% in the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after buying an additional 1,371,775 shares during the last quarter. Vanguard Group Inc. boosted its position in Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares during the last quarter. Marex Group plc bought a new position in shares of Sana Biotechnology during the 2nd quarter worth approximately $10,423,000. JPMorgan Chase & Co. raised its holdings in shares of Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares during the last quarter. Finally, Integral Health Asset Management LLC raised its holdings in shares of Sana Biotechnology by 33.3% in the third quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $7,100,000 after purchasing an additional 500,000 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.